Top Injectable Manufacturer in Uruguay – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 19 hours ago
- 13 min read
Last Updated: August 29, 2026
TL;DR: Uruguay is a small, rich, heavily insured market with an unusually specific barrier for Indian manufacturers, and it is not the one most suppliers talk about. Decreto 18/020, as amended in November 2023, requires importers to prove GMP compliance for every manufacturing site through a certificate issued by a regulator that is an ICH MEMBER or a PAHO/WHO Regional Reference Authority — and India's CDSCO is an ICH Observer, not a Member, and is not a PAHO reference authority. A WHO-GMP certificate alone does not satisfy that article. Where it is missing, the Ministry inspects your plant at your cost, which is a route rather than a refusal. Two corrections while we are here: Uruguay is not a PIC/S member, applicant or pre-applicant, whatever you may have read; and a Uruguayan registration does not travel to Argentina or Brazil, because the MERCOSUR abridged pathway covers products made in a member state, which an Indian product is not. What you get in return is a genuinely attractive market: US$2,076 of health spending per head, only 17 percent of it out of pocket, and the highest dialysis prevalence in a forty-year national series.
Key Takeaways
The binding constraint is the GMP certificate's ISSUER, not its content. Decreto 18/020 article 4, as amended by Decreto 380/023 of 22 November 2023, requires a GMP compliance certificate from a regulator that is an ICH Member or a PAHO/WHO Regional Reference Authority, for every establishment performing any manufacturing stage. CDSCO is an ICH Observer, not a Member. Uruguay's own GMP standard is WHO-based — it internalised MERCOSUR GMC Resolution 15/09, which adopts WHO TRS 908 — so this is a question of who signs, not of what standard applies.
Where the certificate is missing, the decree provides the answer in the same sentence: the Ministry of Public Health carries out the GMP verification inspection itself, at the applicant's cost. That is a defined route, not a dead end, and it is the route most Indian sterile sites will take. Note that it applies site by site, so a split fill, lyophilisation and packaging footprint means more than one inspection to plan for.
Do not sell Uruguay as a MERCOSUR gateway. GMC Resolution 23/95, internalised by article 23 of Decreto 324/999 and expressly preserved when Decreto 18/020 repealed the rest, is an abridged pathway for products manufactured IN a State Party — which excludes an Indian-made product entirely. Its own annex calls mutual recognition a possible future step and calls sanitary vigilance an indelegable national function. Article 13 of Decreto 18/020 recognises therapeutic INDICATIONS approved elsewhere, not registrations.
A Uruguayan-habilitated exclusive representative is legally required. Article 4 requires the applicant company to be habilitated by the regulator and requires medicine importers to be exclusive representatives of the foreign registration holder. Decreto 521/984 adds that the technical director must be a pharmacist holding a degree issued or revalidated by the Universidad de la República. Exclusivity is compulsory, so you cannot register the same product through two importers — negotiate exit and transfer terms up front.
Introduction: Why Uruguay Demands a Premium Injectable Manufacturer in Uruguay
Uruguay is a market that rewards the right kind of supplier and quietly filters out the wrong kind. It is small and shrinking — the World Bank records a 2025 population of 3,384,688, down from 3,388,081 in 2023 — and it is high income, with gross national income per capita of US$24,020 in 2025 and confirmed high-income classification. It spends accordingly: current health expenditure of US$2,076.09 per capita and 9.02 percent of GDP in 2023, with only 17.10 percent of that paid out of pocket. That last number is the one to sit with. A market where third parties pay more than four fifths of the bill is not a volume-generics price play; it is a market where quality documentation, supply reliability and registration durability decide who gets on the list. The clinical demand is real and concentrated in areas injectables serve. GLOBOCAN 2024 records 16,448 new cancer cases and 8,789 deaths, an age-standardised incidence of 272.8 per 100,000 against 197.7 for South America and 194.9 for the world — roughly 1.4 times the regional rate, though part of that gap reflects Uruguay's registry being IARC quality class A while several neighbours have weaker coverage, so read it as a real difference of direction rather than a precise multiple. Renal demand is more striking still: the Registro Uruguayo de Diálisis reported prevalence of 873 per million population for 2023, the highest in its forty-year series, with incidence of 191 per million and diabetic nephropathy the leading entry cause. Tuberculosis incidence is rising, from 34 per 100,000 in 2021 to 47 in 2024.
The regulatory architecture is unusual in a way that catches Indian exporters out, and it is worth being blunt about it. Uruguay has no ANMAT or ANVISA equivalent — the national medicines regulatory authority is, in the words of Decreto 18/020 article 2 itself, the Departamento de Medicamentos of the División Evaluación Sanitaria within the Dirección General de la Salud of the Ministerio de Salud Pública. It is a ministry department, not an agency. It asks for the dossier in ICH CTD format, which is helpful. And then article 4, in a paragraph added only in November 2023, does something that a great deal of older guidance has not caught up with: it names the acceptable issuers of your GMP certificate, and India is not among them. That single paragraph, rather than anything about MERCOSUR or PIC/S or dossier format, is what determines how an Indian sterile manufacturer enters Uruguay. The rest of this article explains it and the two ways through.
What Sets a World-Class Injectable Manufacturer in Uruguay Apart
Start with the article that matters. The second paragraph of article 4 of Decreto 18/020, added by Decreto 380/023 of 22 November 2023, requires importers to demonstrate GMP compliance of the establishments carrying out the various stages of manufacture by means of a GMP compliance certificate issued by the regulatory authority of an ICH member country, or by a national regulatory authority recognised by PAHO/WHO as a Regional Reference Authority; and where no such certificate exists, the Ministry of Public Health carries out the corresponding GMP verification inspections at the applicant's cost. Two facts complete the picture. India's CDSCO participates in ICH as an Observer under the legislative and administrative authorities category, not as a Regulatory Member — and the same trap catches Australia's TGA, which is also an Observer and is frequently misdescribed. And the PAHO Regional Reference Authority list comprises ANMAT, ANVISA, INVIMA, CECMED, ISP Chile, COFEPRIS, Health Canada and the US FDA; India is not on it. So a WHO-GMP certificate from an Indian State Licensing Authority, however impeccable the site behind it, does not by itself satisfy article 4. There is no separate Uruguayan roster of accepted countries to appeal to — the recognition rule simply is article 4, by reference to those two external lists.
That leaves two workable routes and it is worth being clear which is which. The first is to present a GMP certificate from an ICH Member regulator that already covers the site — a US FDA, EU member state, MHRA, Swissmedic, Health Canada, ANVISA, COFEPRIS, MFDS, HSA, SFDA, TFDA, EDA, NAFDAC, SAHPRA, NMPA or Japanese certificate will do the work. Many Indian sterile sites already hold one or more of these, and if yours does, the problem largely disappears. The second is the inspection route the decree itself provides: MSP inspects, you pay. We could not establish whether MSP has previously inspected in India, what it charges or what lead time to expect, and we are not going to invent those numbers — but the route is written into the instrument, which makes it a planning question rather than a barrier. One structural warning: the obligation attaches to every establishment performing any manufacturing stage. If your sterile fill, your lyophilisation and your secondary packaging sit at different addresses, each needs to clear article 4 on its own. Meanwhile the underlying standard is one Indian sites already work to: Uruguay internalised MERCOSUR GMC Resolution 15/09, which adopts WHO TRS 908, by Decreto 440/016, along with Resolution 41/14 on minimum GMP certificate content and Resolution 02/21 on classifying deficiencies as critical, major or other.
Quality Systems Behind Every Injectable Supplied to Uruguay
Two widely repeated claims about Uruguay are simply wrong and both are worth correcting before they cost someone a plan. The first is PIC/S. Uruguay is not a PIC/S Participating Authority, not an applicant, not a pre-applicant and not a former pre-applicant — all four official PIC/S lists were checked and Uruguay appears on none of them. The only Latin American entries anywhere in those lists are Argentina, Brazil, Mexico, Peru and Chile. India is absent from all four as well. So there is no PIC/S mutual-recognition argument to make in either direction. The second is MERCOSUR portability. A Uruguayan registration does not carry into Argentina, Brazil or Paraguay. Resolution 23/95 is an abridged intra-zonal pathway for products elaborated in a State Party, which places an Indian-manufactured product outside its scope entirely; its own annex describes mutual recognition as something that might follow in future if recommendable, states that sanitary vigilance is the indelegable function of each national authority, and requires products to be registered with the receiving state's agency regardless. Sell Uruguay as Uruguay.
On the mechanics that follow approval, Uruguay is stricter than its size suggests and the strictness is mostly about follow-through. Article 10 is unforgiving on completeness: a refusal carries a 180-day bar on re-filing and missing documents cannot be added late. There is no overall statutory approval clock in the decree — anyone quoting you an approval time is quoting anecdote — but there is defined machinery: thirty calendar days for you to answer each query, up to three query rounds, and up to 120 calendar days for the authority to analyse each response. Registration runs five years and renewal must be filed before expiry and no more than ninety days early, with a fresh CPP and a fresh article-4-compliant GMP certificate each time. Then the commercial obligations bite: you must notify launch ten working days ahead and actually launch within a year, extendable by six months, after which annual extensions cost five times the original fee up to five years before the registration is annulled; three consecutive years of unavailability ends it automatically; and any supply interruption beyond thirty days must be notified and justified. Uruguay is a market that expects you to stay. Fees are 30 UR plus 5 UR per active principle — we have deliberately not converted that, because we did not verify the current Unidad Reajustable value.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Uruguay for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Uruguay our starting position is candid: we do not tell buyers that our WHO-GMP certification satisfies article 4, because it does not, and a partner who tells you otherwise has not read the November 2023 amendment. What we do is prepare for the inspection route properly — site master file, validation and qualification packages, environmental monitoring and media fill records, deviation and CAPA history assembled to the standard an inspecting authority arrives expecting, and classified against the critical, major and other taxonomy Uruguay adopted through Resolution 02/21 by Decreto 173/022. Because the underlying standard is WHO TRS 908, internalised by Decreto 440/016, the substance of what an MSP inspector assesses is the substance our WHO-GMP system is already built on. It is the signature that is missing, not the system.
On the dossier itself, Uruguay's CTD requirement under article 6, referencing ICH guide M4, plays to our strengths: our master files are maintained in CTD structure, so what Uruguay asks for is a translation and legalisation exercise rather than a rebuild. We prepare the documentation in Spanish, with the scientific-technical parts flagged for the authority's discretion to accept another language, and we handle apostille or legalisation of the CPP, the GMP certificate and the sworn declarations as a single workstream rather than as a series of surprises. Analytical work is referenced to European Pharmacopoeia and USP texts from the last three years, as article 12 requires. Our stability programmes run under ICH Q1A(R2) and Q1B, and here we will flag an open question rather than paper over it: the applicable Uruguayan stability instrument is MERCOSUR Resolution 53/96, internalised by Ordenanza 688/998, whose text we did not open, and Resolution 53/96 assigns storage conditions by the climate the product is destined for without ever naming Uruguay or containing any Zone IVa/IVb split. We therefore do not state Uruguay's climatic zone, and we would confirm it with the Departamento de Medicamentos before committing a protocol. Any supplier quoting you a Uruguayan zone confidently should be asked which instrument assigns it.
Finally, we understand that Uruguay has four buyers and that conflating them wastes quarters. ASSE, the state provider established by Ley 18.161, runs its own medicine tenders through its procurement department and publishes them on Compras Estatales. The Unidad Centralizada de Adquisiciones, created by article 163 of Ley 18.172 within the finance ministry, buys medicines, hospital supplies and food as an agent on behalf of member state bodies rather than for its own account. The Fondo Nacional de Recursos is different in kind — a persona pública no estatal outside the state tendering code, which finances high-complexity procedures and high-cost medicines and, under its own Reglamento de Compras in force since August 2020, buys by direct contracting after negotiation or by price competition among invited suppliers, restricted to suppliers formally established in the country or their accredited representatives, and requiring the product to be registered in Uruguay. And the IAMC mutualistas under the national integrated health system each procure individually and do not publish. On the state side, registration in RUPE is mandatory to contract, and a foreign entity can enrol directly using a foreign tax code — so the local partner is a practical necessity for document verification and presence rather than a formal bar. The binding requirement remains article 4: the product registered, the importer habilitated and exclusive. Trade context: India reported US$7,410,925 of HS Chapter 30 exports to Uruguay in 2025, recovering from a US$4,317,705 trough in 2024 against US$7,174,172 in 2023, and India opened a resident embassy in Montevideo on 15 May 2026. There is no India–Uruguay pharmaceutical or health memorandum of understanding in the Ministry of External Affairs brief dated 20 July 2026 — a verified absence, and one worth knowing before anyone tells you otherwise.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Will our Indian WHO-GMP certificate be accepted in Uruguay?
Not on its own, and this is the most important thing on this page. Article 4 of Decreto 18/020, as amended in November 2023, requires the GMP compliance certificate to come from a regulator that is an ICH Member or a PAHO/WHO Regional Reference Authority. India's CDSCO is an ICH Observer, not a Member, and is not among the eight PAHO Regional Reference Authorities. Note that this is about the issuer, not the standard — Uruguay's own GMP text is WHO TRS 908, internalised through MERCOSUR Resolution 15/09 by Decreto 440/016, which is the standard your WHO-GMP system already meets. If you hold a GMP certificate from an ICH Member authority covering the site, use it. If you do not, the decree routes you to an MSP inspection at your own cost, and that applies to every site performing any manufacturing stage.
Does a Uruguayan registration open Argentina and Brazil through MERCOSUR?
No, and planning on it is a costly mistake. MERCOSUR GMC Resolution 23/95, which Uruguay internalised through article 23 of Decreto 324/999 and expressly preserved when Decreto 18/020 repealed the remainder of that decree, provides an abridged pathway for products elaborated in a State Party that are similar to products already registered in the receiving state. A product manufactured in India falls outside its scope from the start. Beyond that, the resolution's own annex describes mutual recognition of registrations as something that might follow in future if it proves recommendable, states that sanitary vigilance is the indelegable function and responsibility of each national authority, and requires that products be registered with the regulatory agency of the State Party concerned. Article 13 of Decreto 18/020 is sometimes cited as recognition; it is not — it lets the authority accept therapeutic indications already approved on clinical evidence by ICH Member or PAHO reference regulators.
Is Uruguay a PIC/S member, and does that help us?
Uruguay is not a PIC/S member, applicant, pre-applicant or former pre-applicant. We checked all four official PIC/S lists and Uruguay appears on none of them; the only Latin American entries are Argentina, Brazil, Mexico, Peru and Chile. India is not on any of the four either. If you have seen Uruguayan PIC/S status asserted, it is wrong. Separately, Uruguay does not appear on WHO's list of WHO-Listed Authorities, on the transitional WLA list of December 2025, or on the August 2026 list of regulators at maturity level 3 or 4 — on which India's CDSCO does appear at ML3 for vaccines. To be precise about what that means: WHO does not publish ML1 or ML2 results, so the correct statement is that Uruguay is not listed, not that it was assessed and found wanting.
Do we need a Uruguayan representative, and what does exclusivity mean for us?
You need one, and the exclusivity is compulsory rather than commercial. Article 4 requires the applicant company to be duly habilitated by the regulator — including companies in free-trade or free-port zones — and requires medicine importers to be exclusive representatives, for the products being registered, of the pharmaceutical company holding the registration in the country of origin. Decreto 521/984 adds that import-only establishments must first register as representatives of foreign industrial establishments or as drogueras, that the technical direction must be held by a pharmacist whose degree was issued or revalidated by the Universidad de la República, and that representatives must be inscribed in the ministry's register of representatives, which fixes their liability for the represented manufacturer's products. Practically: your Uruguayan partner becomes the registration holder, you cannot run two importers for the same product, and transfer and exit terms should be negotiated before filing, not after.
Who actually buys injectables in Uruguay?
Four channels, and they are not interchangeable. ASSE, the state health services administration under Ley 18.161, is a decentralised service with its own board that runs its own medicine tenders itemised by international non-proprietary name and publishes them on Compras Estatales. The Unidad Centralizada de Adquisiciones sits within the finance ministry under article 163 of Ley 18.172 and buys medicines, hospital supplies and food on behalf of and for the account of member state bodies, acting as an agent. The Fondo Nacional de Recursos, created by Ley 16.343, is a persona pública no estatal governed by an honorary commission and sits outside the state tendering code; it finances high-complexity procedures and high-cost medicines and negotiates and buys those medicines itself, by direct contracting or restricted price competition among suppliers established in the country or their accredited representatives, and it requires Uruguayan registration. The IAMC mutualistas, the private non-profit integral providers within the national integrated health system, each procure individually and do not publish. Whether any joint purchasing body exists among them we could not verify either way.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments